In conclusion, our data indicate potential application of specific KLK7 inhibitors to regulate KLK7 activity in the development of obesity and counteract obesity-associated inflammation and metabolic diseases. This evidence concerns the gene KLK7 and obesity due to melanocortin 4 receptor deficiency.